Characteristics and outcome of Swedish AML patients 60 to 84 years of age diagnosed 2007 to 2010,49 according to performance status (PS) and treatment intensity compared with patients in high-dose lenalidomide study by Fehniger et al51
| Patients . | N . | Median age, y . | Performance status 0/I/II, % . | De novo AML, % . | Death rate at 30 d, % . | Median OS, mo . | OS, 1 y, % . | OS, 3 y, % . |
|---|---|---|---|---|---|---|---|---|
| Sweden 60-84 y | ||||||||
| PS 0-II | 511 | 72 | 21/63/16 | 62 | 10 | 10 | 44 | 21 |
| PS 0 | 107 | 69 | 100/0/0 | 69 | 5 | 17 | 64 | 35 |
| PS I | 320 | 71 | 0/100/0 | 63 | 10 | 10 | 44 | 18 |
| PS II | 84 | 77 | 0/0/100 | 49 | 15 | 3 | 22 | 12 |
| PS 0-I | 427 | 71 | 25/75/0 | 64 | 8 | 12 | 49 | 22 |
| Intensive | 284 | 68 | 29/71/0 | 70 | 5 | 15 | 58 | 27 |
| Palliative | 129 | 77 | 16/84/0 | 50 | 16 | 5 | 30 | 12 |
| Lenalidomide study | 33 | 71 | 49/39/12 | 70 | 24 | 4 | 30 | 0 |
| Patients . | N . | Median age, y . | Performance status 0/I/II, % . | De novo AML, % . | Death rate at 30 d, % . | Median OS, mo . | OS, 1 y, % . | OS, 3 y, % . |
|---|---|---|---|---|---|---|---|---|
| Sweden 60-84 y | ||||||||
| PS 0-II | 511 | 72 | 21/63/16 | 62 | 10 | 10 | 44 | 21 |
| PS 0 | 107 | 69 | 100/0/0 | 69 | 5 | 17 | 64 | 35 |
| PS I | 320 | 71 | 0/100/0 | 63 | 10 | 10 | 44 | 18 |
| PS II | 84 | 77 | 0/0/100 | 49 | 15 | 3 | 22 | 12 |
| PS 0-I | 427 | 71 | 25/75/0 | 64 | 8 | 12 | 49 | 22 |
| Intensive | 284 | 68 | 29/71/0 | 70 | 5 | 15 | 58 | 27 |
| Palliative | 129 | 77 | 16/84/0 | 50 | 16 | 5 | 30 | 12 |
| Lenalidomide study | 33 | 71 | 49/39/12 | 70 | 24 | 4 | 30 | 0 |